Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - glimepiride -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - glimepiride -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - glimepiride -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - glimepiride -

United States - English - NLM (National Library of Medicine)

cardinal health - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 2 mg - glimepiride tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies (14.1)]. glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: sulfonamide derivatives: patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. reported hypersensitivity reactions include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g. anaphylaxis, angioedema, stevens-johnson syndrome, dyspnea) [see warnings and precautions (5.2) and adverse reactions (6.2)]. there are no adequate and well-controlled studies of glimepiride in pregnant w

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 4 mg - glimepiride tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies (14.1) ]. glimepiride tablets usp should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: sulfonamide derivatives: patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. reported hypersensitivity reactions include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, stevens-johnson syndrome, dyspnea) [see warnings and precautions (5.2) and adverse reactions (6.2) ]. pregnancy category c there are no adequate and well-controlled studies of

United States - English - NLM (National Library of Medicine)

bionpharma inc. - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 1 mg - glimepiride tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies (14.1) ]. glimepiride tablets usp should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: -  glimepiride or any of the product’s ingredients [see warnings and precautions (5.2)]. sulfonamide derivatives: patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. reported hypersensitivity reactions include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, stevens-johnson syndrome, dyspnea) [see warnings and precautions (5.2) and adverse rea

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - glimepiride (unii: 6ky687524k) (glimepiride - unii:6ky687524k) - glimepiride 1 mg - glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see clinical studies (14.1)]. limitations of use glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: available data from a small number of published studies and postmarketing experience with glimepiride tablets use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal outcomes. however, sulfonylureas (including glimepiride) cross the placenta and have been associated with neonatal adverse reactions such as hypoglycemia. therefore, glimepiride tablets should be discontinued at least two weeks before expected delivery (see clinical considerations). poorly controlled diabetes in pregnancy is also

Canada - English - Health Canada

pharmascience inc - glimepiride - tablet - 4mg - glimepiride 4mg - sulfonylureas

Canada - English - Health Canada

apotex inc - glimepiride - tablet - 4mg - glimepiride 4mg - sulfonylureas